

Open access • Posted Content • DOI:10.1101/2020.10.20.20203927

Characterization of a COPD-Associated NPNT Functional Splicing Genetic Variant in Human Lung Tissue via Long-Read Sequencing — Source link 🗹

Aabida Saferali, Zhonghui Xu, Gloria M. Sheynkman, Craig P. Hersh ...+5 more authors

Institutions: Brigham and Women's Hospital, University of Virginia, University of North Carolina at Chapel Hill, University of California, Santa Cruz

Published on: 03 Nov 2020 - medRxiv (Cold Spring Harbor Laboratory Press)

Topics: Genome-wide association study and Exon

Related papers:

- COPD GWAS variant at 19q13.2 in relation with DNA methylation and gene expression
- · Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis
- Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks.
- · Whole genome sequence analysis of pulmonary function and COPD in 19,996 multi-ethnic participants
- Meta-analysis of exome array data identifies six novel genetic loci for lung function



Characterization of a COPD-Associated *NPNT* Functional Splicing Genetic Variant in Human Lung Tissue via Long-Read Sequencing

Aabida Saferali¹, Zhonghui Xu¹, Gloria M. Sheynkman^{2,3,4}, Craig P. Hersh^{1,5}, Michael H. Cho^{1,5}, Edwin K. Silverman^{1,5}, Alain Laederach⁶, Christopher Vollmers⁷, Peter J. Castaldi^{1,8}

¹Channing Division of Network Medicine, Brigham and Women's Hospital

²Department of Molecular Physiology and Biological Physics, University of Virginia

³Center for Public Health Genomics, University of Virginia

⁴UVA Cancer Center, University of Virginia

⁵Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital

⁶Department of Biology, University of North Carolina at Chapel Hill

⁷Department of Biomolecular Engineering, Cellular, Cellular, and Developmental Biology, University of California Santa Cruz

⁸Division of General Medicine and Primary Care, Brigham and Women's Hospital

Abstract:

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. Genomewide association studies (GWAS) have identified over 80 loci that are associated with COPD and emphysema, however for most of these loci the causal variant and gene are unknown. Here, we utilize lung splice quantitative trait loci (sQTL) data from the Genotype-Tissue Expression project (GTEx) and short read sequencing data from the Lung Tissue Research Consortium (LTRC) to characterize a locus in nephronectin (NPNT) associated with COPD case-control status and lung function. We found that the rs34712979 variant is associated with alternative splice junction use in NPNT, specifically for the junction connecting the 2nd and 4th exons (chr4:105898001-105927336) ($p=4.02 \times 10^{-38}$). This association colocalized with GWAS data for COPD and lung spirometry measures with a posterior probability of 94%, indicating that the same causal genetic variants in *NPNT* underlie the associations with COPD risk, spirometric measures of lung function, and splicing. Investigation of NPNT short read sequencing revealed that rs34712979 creates a cryptic splice acceptor site which results in the inclusion of a 3 nucleotide exon extension, coding for a serine residue near the N-terminus of the protein. Using Oxford Nanopore Technologies (ONT) long read sequencing we identified 13 NPNT isoforms, 6 of which are predicted to be protein coding. Two of these are full length isoforms which differ only in the 3 nucleotide exon extension whose occurrence differs by genotype. Overall, our data indicate that rs34712979 modulates COPD risk and lung function by creating a novel splice

acceptor which results in the inclusion of a 3 nucelotide sequence coding for a serine in the nephronectin protein sequence. Our findings implicate *NPNT* splicing in contributing to COPD risk, and identify a novel serine insertion in the nephronectin protein that warrants further study.

1 Introduction

The development of chronic obstructive pulmonary disease (COPD) is influenced by genetic susceptibility factors in addition to environmental exposures. Recent genome-wide association studies (GWAS) have identified over 80 distinct genetic loci that influence susceptibility to COPD and emphysema¹, but for most of these loci the causal genetic variants and effector genes are unknown. By identifying the functional genetic variants in these GWAS loci and elucidating the biological mechanisms through which they influence disease susceptibility, causal mechanisms of COPD may be discovered.

9 The large majority of causal GWAS variants reside in the non-coding genome and disrupt 10 gene regulatory elements. As a result, expression quantitative trait locus (eQTL) studies that 11 associate genetic variants to gene expression values have been used to identify functional gene 12 targets of GWAS-identified loci. In COPD, this approach has identified putative causal variants affecting the expression of HHIP², FAM13A³, TGFB2⁴, and ACVR1B⁵. However, eOTL studies 13 14 do not capture all of the potentially relevant functional mechanisms through which causal 15 variants may alter gene expression. In particular, the alteration of gene splicing and isoform 16 ratios is an important disease-causing gene regulatory mechanism that is not well captured by gene-level eQTL analyses^{6,7}. 17

18 A genome-wide significant and replicated genetic association signal for respiratory 19 phenotypes near NPNT may harbor a causal splicing variant, because the pattern of association at 20 this locus is characterized by a single, clear lead SNP association that is located 5 nucleotides 21 upstream from the 5' splice site of the second exon in NPNT. We hypothesized that this region 22 contains a functional variant that alters NPNT splicing. We utilized short and long-read RNA 23 sequencing from human lung tissues to identify a causal splicing variant, rs34712979; to catalog 24 the isoform variability of NPNT in the human lung; and to characterize the effects of rs34712979 25 on isoform usage rates.

26

27 Methods

28 Genetic association analysis, splicing QTL, and colocalization results

Summary genome-wide association study (GWAS) statistics were used from our previous study of $COPD^1$ and two lung function phenotypes, FEV_1 and FEV_1/FVC

31 (<u>http://ldsc.broadinstitute.org/ldhub/</u>)⁸. Leafcutter splicing QTL (sQTL) significant results⁹ were

27	abtained for all ticques	from the CTE	Doutol (httm://www	w atown antal a	na/hama/datasata) and
32	obtained for all tissues	from the GIEX	Portal (https://ww	w.glexbortal.o	rg/nome/datasets), and
					- 8

- 33 complete lung sQTL results were obtained from the Anvil GTEx Terra workspace. Multiple
- 34 colocalization for GWAS and sQTL results was performed using the moloc R package
- 35 (<u>https://github.com/clagiamba/moloc</u>). Moloc analyses were performed using default parameters
- 36 for prior variance of the approximate Bayes factor (ABF, prior_var = c(0.01, 0.1, 0.5)) and
- 37 default parameters for the prior likelihood that a given SNP is causal for one trait, pairs of traits,
- or all traits (priors = c(1e-04, 1e-06, 1e-07)). Linkage disequilibrium (LD), evolutionary
- 39 conservation, and overlap with regulatory elements were identified for individual single
- 40 nucleotide polymorphisms (SNPs) with Haploreg
- 41 (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php). Posterior causal probabilities
- 42 based on strength of genetic association and local LD patterns were determined using the PICS
- 43 algorithm (https://pubs.broadinstitute.org/pubs/finemapping/pics.php).¹⁰
- 44

45 Splicing analysis in short read RNA-seq data from GTEx lung tissue samples

- 46 With dbGaP approval, RNA-seq BAM files and whole genome sequencing VCF files for
- 47 lung tissue samples in GTEx V8 release were accessed on Google Cloud via the AnVIL GTEx
- 48 Terra workspace (<u>https://app.terra.bio/#workspaces/anvil-datastorage/AnVIL_GTEx_V8_hg38</u>).
- 49 To obtain splicing junctional counts for each genotype and visualize with Sashimi plots, a
- 50 Docker image (<u>https://hub.docker.com/repository/docker/pacifly/splice-plot-app</u>) was built on

51 the Python package SplicePlot¹¹ (<u>https://github.com/wueric/SplicePlot</u>) and its dependencies, and

- 52 a WDL workflow
- 53 (https://portal.firecloud.org/?return=terra#methods/zxu_spliceplot/spliceplot/18) was created and

54 executed via Cromwell engine to run SplicePlot functionalities on Google Cloud. The splicing

55 junctional count method in SplicePlot was adapted to accommodate novel junctions missed from

- 56 the alignment.
- 57
- Lung Tissue Research Consortium Samples, short-read RNA sequencing, and whole genome
 sequencing
- 60 The Lung Tissue Research Consortium (LTRC) is an NHLBI-sponsored collection of 61 lung and blood tissues collected from patients undergoing thoracic surgery who completed a
- 62 standard questionnaire, pulmonary function testing, and chest computed tomography (CT)

63 imaging. Through the NHLBI Trans-Omics and Precision Medicine (TOPMed) program, LTRC

64 whole-genome sequencing (WGS) data were generated at Broad Genomics and lung RNA-seq

65 were generated at the University of Washington, and 1,335 LTRC samples with RNA-seq and

66 WGS passing quality control filters were analyzed in this study. Briefly, RNA-seq data were

67 generated using paired-end Illumina sequencing from poly-A selected libraries to an average

depth of 67 million mapped reads. Methods for TOPMed WGS are available at

69 https://www.nhlbiwgs.org/topmed-whole-genome-sequencing-methods-freeze-8.

70

71 Long read RNA-seq analysis in human lung samples from the LTRC

We conducted targeted Oxford Nanopore Technologies (ONT) long read sequencing on RNA from 10 human lung samples from the LTRC which were selected to include five samples from each homozygous class (i.e., GG genotype, AA genotype) of rs34712979. For each of these ten samples, 100-200ng of total RNA was used to generate full-length cDNA using a modified Smart-seq2 protocol¹². The enrichment and library generation procedures are described in detail in the Supplemental Methods.

78 Enriched re-amplified cDNA from two independent enrichment reactions was sequenced on a MinION 9.4.1 flow cell or a MinION 10.3 flow cell using the R2C2 method¹³⁻¹⁶. For each 79 80 run, lug of DNA was prepared using the LSK-109 kit according to the manufacturer's 81 instructions with only minor modifications. End-repair and A-tailing steps were both extended 82 from 5 minutes to 30 minutes. The final ligation step was also extended to 30 minutes. Each run 83 took 48 hours and the resulting data in Fast5 format was basecalled using the high accuracy 84 model of the gpu accelerated Guppy algorithm (9.4.1 flow cell: version 3.4.5+fb1fbfb with 85 config file dna_r9.4.1_450bps_hac.cfg config file; 10.3 flow cell: version 3.6.1+249406c with 86 config file dna_r10_450bps_hac.cfg). To generate R2C2 consensus reads for each sample, we 87 processed and demultiplexed the resulting raw reads using our C3POa pipeline 88 (https://github.com/rvolden/C3POa). R2C2 reads were analyzed to identify and quantify 89 isoforms using version 3.5 of Mandalorion (-O 0,40,0,40 -r 0.01 -i 1 -w 1 -n 2 -R 5) 90 (https://github.com/rvolden/Mandalorion-Episode-III). Isoforms were categorized using the sqanti qc.py script of the SQANTI¹⁷ program with slight modifications to make it compatible 91

92 with Python3.

93	For NPNT isoform quantification (i.e., usage analysis), the proportion of isoform usage			
94	for each sample was calculated by dividing the number of reads for each isoform by the total			
95	number of isoform reads aligning to the NPNT locus. Differences in isoform usage between			
96	genotype classes were identified using the Mann-Whitney test. For certain analyses, isoform			
97	reads were collapsed based on whether they contained a 3 nucleotide exon extension. To			
98	quantify the number of reads containing this TAG sequence at the 5' end of the second exon, we			
99	extracted the following 30-mers from the fasta files for each sample using the 'grep' command:			
100				
101	AGTTCGACGGGAG <u>TAG</u> GTGGCCCAGGCAAA			
102	CGAGTTCGACGGGAGGTGGCCCAGGCAAAT			
103				
104	NPNT protein sequence analysis			
105	Protein sequence analysis was performed using Uniprot ¹⁸ to identify NPNT protein domains. The			
106	Chou and Fasman Secondary Structure Prediction server ¹⁹ was used to characterize the impact of			
107	sequence changes to NPNT structure.			
108				
109	Results			
110	Genetic association signals for respiratory phenotypes in NPNT			
111	Genome-wide significant association signals near NPNT have been identified for COPD			
112	and various measures of lung function, and previous colocalization and fine mapping analyses			
113	have implicated rs34712979 as the most likely causal variant for the COPD association near			
114	NPNT ¹ . We obtained the summary GWAS statistics for the most recent GWAS meta-analyses of			
115	COPD, FEV ₁ , and FEV ₁ /FVC and compared the genetic association signal for each of these			
116	phenotypes. In each case, the variant with minimal p-value was rs34712979, a common variant			
117	with a minor allele frequency of 23% in the 1,000 Genomes European (EUR) population. Using			
118	the PICS algorithm, we determined that the estimated posterior probability that rs34712979 was			
119	the causal variant for each of these associations was between 94-100%. This variant is in strong			
120	linkage disequilibrium with only one other common variant, rs6828309 ($r^2 = 0.81$ in EUR).			
121	Supplemental Table 1 shows that rs34712979 is highly conserved and overlaps promoter and			
122	enhancer elements in multiple cell types, which is not the case for rs6828309 (Supplemental			

Table 1). The minor A allele of rs34712979 is associated with lower measures of lung functionand increased risk of COPD (odds ratio=1.18).

125

126 An NPNT splicing association signal in human lung tissue colocalizes with GWAS associations 127 To determine whether the genetic associations near NPNT to pulmonary phenotypes may 128 be explained by genetic effects on splicing, we examined leafcutter quantitative trait locus (OTL) 129 results from 49 tissues obtained from a total of 838 subjects in GTEx version 8. We observed 130 that rs34712979 was associated with splicing ratios for three exon-exon junctions in a total of 18 131 tissues that connect the first and second, second and fourth, and third and fourth exons of NPNT 132 (GENCODE v32) (Supplemental Table 2). Focusing on lung tissue, the most relevant tissue for 133 COPD, we observed that rs34712979 was associated with multiple splicing ratios at a nominal p-134 value threshold of p<0.001 (Supplemental Table 3), with the association for the junction 135 connecting the 2nd and 4th exons (chr4:105898001-105927336) exceeding genome-wide 136 significance. To better understand the effect of rs34712979 on splicing in human lung, we 137 identified 27 subjects in GTEx homozygous for the A allele of rs34712979 and compared the 138 distribution of junctional reads from lung RNA in these subjects against 27 randomly selected 139 samples from the other two genotype classes (Figure 1), and found that the A allele results in 140 higher rates of inclusion of the 3rd exon. Upon further investigation of junctional reads flanking 141 exon 2 we discovered the presence of a novel splice site acceptor at the 5' end of exon 2 142 associated with the A allele. This novel cryptic splice site was not detected in the sQTL analysis 143 as 99.6% of reads using the cryptic splice site were soft-clipped (ie. portions of the read were 144 masked due to a mismatch with the reference genome) and therefore were not included in the 145 Leafcutter clustering step.





Figure 1. GTEx Leafcutter lung sQTL results for effect of rs34712979 on splice junctions
involving the 2nd-4th exons of *NPNT* in leafcutter splicing analysis from short-read RNAseq in
515 GTEx samples (A) and in junctional reads from 27 samples from each genotype class of
rs34712979 (B). The 3 nucleotide alternatively spliced exonic extension sequence is shown in
the inset window of panel B.

166

167 To confirm that the lung sQTL signals in this region overlap with the GWAS association 168 signals, we performed multiple colocalization using the moloc method which resulted in an 169 estimated 94% probability of a shared causal variant for the three genetic association signals and 170 the lung splicing signal for the 2nd and 4th exons of NPNT (chr4:105898001-105927336). 171 rs34712979 had the best individual SNP posterior probability across all evaluated scenarios, with 172 a posterior probability of 94% for the scenario of shared colocalization across all four datasets 173 (Supplemental Table 4). The local association plots for each of the association signals near 174 *NPNT* is shown in Figure 2. 175



176

177 Figure 2. Local association plots for genetic association near NPNT to COPD (A,

Sakornsakolpat 2019), FEV1 (B), FEV1/FVC (C, Shrine 2019), and GTEx Leafcutter lung sQTL
analyses (D).

180

181 rs34712979 creates an alternative splice acceptor site

rs34712979 is located 5bp upstream of the second exon of *NPNT*, so we examined the
sequence content in this region for motifs that may alter splicing, and we observed that the minor
A allele of rs34712979 creates a cryptic AG splice acceptor that would result in a 3 nucleotide 5'
exon extension in exon 2. In other words, the A allele creates a NAGNAG splice site, which
contains adjacent AG acceptor sites that can be variably used^{20,21}. Open reading frame analysis

indicates that this results in an additional in-frame AGT codon, coding for serine, spanning theboundaries of the first and second exon (Figure 3).

189 To confirm this effect in human lung samples, we queried short-read RNA-seq data from 190 human lung samples in GTEx and confirmed that samples with the A allele demonstrate 191 preferential use of the cryptic versus the annotated splice acceptor site (Figure 4). We further 192 confirmed that this phenomenon occurs in a larger set of 1,335 lung samples from the LTRC

193 (Figure 4).







Figure 3. The A allele of rs34712979 creates an alternative splice acceptor site resulting in inclusion of a serine at the 5' splice site of exon 2.



207

Figure 4. Violin plot of exon 2 alternative splice site usage in short-read RNA-seq from A)

209 LTRC and B) GTEX Lung Tissue Samples.

210

211 Characterization of rs34712979 Allelic Effects on NPNT Isoform Usage

212 To determine the effect of rs34712979 on full-length NPNT isoforms, we performed 213 targeted enrichment for NPNT transcripts followed by ONT long-read sequencing in lung tissue 214 samples from the LTRC selected to include 5 subjects from each homozygote class of 215 rs34712979. The experiment yielded 24,747 reads mapping to NPNT. Thirteen high confidence 216 isoforms were detected, 12 of which were novel (Supplemental Table 1). Six of these isoforms, 217 including one antisense isoform, have open reading frames indicating that they have protein-218 coding potential. Two protein coding isoforms containing exon 2 utilize the cryptic splice 219 acceptor, while two isoforms utilize the annotated splice acceptor (Figure 5, panel A).

220 Isoform usage differed between rs34712979 genotype classes. On a per-isoform basis, 9 221 of the 13 isoforms show differential usage between the two homozygous genotype classes 222 (Mann-Whitney p < 0.05). Focusing on the putative protein-coding isoforms, we found that the 223 full length annotated isoform 'coding_5' (corresponding to ENST00000379987.6) is more highly 224 expressed in the GG genotype class, while isoform 'coding_1', also full length, is highly 225 expressed in 4 out of 5 subjects with the AA genotype (Figure 6). The three short isoforms are 226 also differentially expressed by genotype, with isoforms 'coding 3' and 'coding 4' more highly 227 expressed in AA. Looking specifically at usage of the alternative or canonical splice acceptor 228 site at the 5' end of exon 2, we observed 10 isoforms that include the second exon, with five 229 isoforms each using the alternative or canonical splice acceptor. Collapsing these isoforms by 230 splice site usage demonstrates markedly increased usage of the alternative splice site in the AA 231 genotype, with essentially no usage of the alternative site in 4 of the 5 GG genotype class 232 samples (Figure 6, panel E). We confirmed the presence of the 3-nucleotide 5' exon extension 233 sequence in full length reads by counting the reads containing a 30-bp sequence centered on the 234 TAG triplet located after the novel splice junction and compared this to the number of reads 235 containing a corresponding 30-bp sequence without the TAG. Table 1 shows the clear 236 association between the AA genotype and the 3-nucleotide exon extension event.

- 237
- 238
- 239
- 240
- 241
- 242

medRxiv preprint doi: https://doi.org/10.1101/2020.10.20.20203927; this version posted November 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Figure 5. Isoforms detected by long read sequencing in 10 human lung tissues predicted to be coding or noncoding (A) * Indicates isoforms utilizing the novel splice acceptor site resulting in a three nucleotide 5' extension of exon 2. The isoform usage profile differs markedly between rs34712979 GG (B) and AA homozygotes (C).



274

Figure 6. Long read sequencing confirms the presence of two full length isoforms, one incorporating a 3 bp intronic sequence (A) and the other which is fully annotated (B). Out of the two short isoforms (coding isoforms 2 and 3) which contain exon 2, one includes the upstream cryptic splice site and is more highly expressed in samples homozygous for the rs34712979 AA genotype (C), while the other is predominantly expressed in the GG genotype (D). All isoforms using the cryptic splice site combined have increased expression in the AA genotype with minimal expression in GG.

282

283 Protein sequence analysis

The serine residue 5' exon extension is inserted 24 residues from the N-terminus of NPNT protein, and four amino-acids after the end of the predicted signal peptide. Protein secondary structure analysis of NPNT isoform sequences with and without the 3 nucleotide exon extension revealed that the serine residue results in the perturbation of an alpha-helical segment with a turn motif (Supplemental Figure 1).

- 289
- 290

291 Discussion

292 Our results provide strong support for the hypothesis that rs34712979 is a functional 293 GWAS variant that acts by altering isoform usage of NPNT. Our analyses led to three main 294 findings: 1) the genetic association patterns of association to COPD, FEV1 and FEV1/FVC near 295 NPNT are highly likely to share rs34712979 as a causal genetic variant, 2) the A allele of 296 rs34712979 creates an alternative splice acceptor site that results in a 3-nucleotide exon 297 extension at the 5' end of exon 2 that is predicted to result in the addition of a serine to the 298 NPNT protein, and 3) the A allele alters NPNT isoform usage. The genetic association patterns 299 reflect the cumulative data of hundreds of thousands of subjects, and the splicing effects were 300 demonstrated in lung RNA from over 1,000 subjects in two different human cohorts.

301 NPNT, or nephronectin, is an extracellular protein involved in tissue development, 302 remodeling, and repair. It was first identified in the context of the search for a novel ligand for integrin $\alpha 8\beta 1^{22,23}$ and was shown to be necessary for normal kidney development in murine 303 models²⁴. NPNT has also been linked to osteoblast differentiation and bone remodeling²⁵. 304 invasiveness of breast cancer²⁶, and pulmonary silicosis²⁷. Full-length NPNT protein includes 305 306 five epidermal growth factor (EGF)-like functional domains followed by a meprin, A-5 protein, receptor protein-tyrosine phosphatase mu (MAM), and an Arg-Gly-Asp (RGD) integrin-binding 307 308 domain. The most well-described function of NPNT is as an extra-cellular matrix protein that 309 binds integrin $\alpha 8\beta 1$ through its RGD domain. Recently, NPNT has been identified in 310 extracellular vesicles secreted by a murine breast cancer cell line, and full-length NPNT has been 311 reported to undergo post-translational modifications including cleavage to a shorter 20-kd isoform²⁸. Full length NPNT has also been shown to be highly expressed in human pneumocytes 312 in the Human Protein Atlas project²⁹. Previous studies have identified NPNT as a potential 313 314 effector gene via association between lung function and mRNA levels and NPNT staining in pulmonary endothelial and alveolar epithelial cells³⁰. In our study, we identify two full length 315 316 NPNT isoforms, one of which is fully annotated while the other utilizes a cryptic splice acceptor 317 in exon 2, in addition to three shortened isoforms that are likely protein coding. Within the pair 318 of long isoforms and within the pair of short isoforms, they differ only in the inclusion of a three 319 nucleotide 5' exon extension coding for a serine residue near the N-terminus of the protein. 320 Additional studies are needed to confirm the extent to which these differences at the RNA level 321 translate to differences in pulmonary protein isoform content, structure and function.

322 The NPNT genetic association lies in a region first described in association with lung function^{31,32}. Subsequent studies confirmed an association with COPD and also identified two 323 independent signals at this locus³³. Several genes in this region have previously been 324 325 hypothesized to be the effector genes using eQTL studies, including the nearby genes GSTCD 326 and *INTS12*. These two genes harbor eQTL in blood and lung, and prior studies have found 327 correlations between GSTCD and INTS12 mRNA with lung function and variable expression during lung development³⁴. Additional studies identified *NPNT* as another potential effector gene 328 at this locus^{1,30}, indicating that the genetic association at this locus likely involves several 329 330 different genes and mechanisms.

331 From a genetic standpoint, the most clear and compelling genetic associations of NPNT 332 to common disease colocalize to an area including the second exon with clear evidence that rs34712979 is a causal variant contributing to the association signals to lung function^{8,35} and 333 334 COPD¹. Our RNA-seq analyses provide strong evidence that the A allele of rs34712979 (which 335 is associated with decreased pulmonary function and increased COPD risk) creates an alternative 336 splice acceptor site at the 5' end of the second exon, and this site is preferentially used relative to 337 the annotated splice site on haplotypes containing the A allele. Usage of this alternative splice 338 site results in the inclusion of a serine residue near the N-terminus of the protein that is predicted 339 to perturb an alpha-helical segment with a turn motif. In addition to this alternative acceptor site 340 usage, the A allele substantially alters NPNT isoform usage patterns. While some of the isoform 341 changes can be directly explained by the second exon alternative splice site usage event, our 342 analysis also identified allelic effects on downstream splicing events as well. The mechanisms 343 that may link usage of alternative splice site to other splicing events remain to be elucidated.

As is characteristic of human GWAS associations, the penetrance of the rs34712979 A allele is low, indicating that either the overall effect of this allele on biological function is subtle or that the effect is large but occurs only in restricted sub-populations. Additional research on *NPNT* isoform expression at the RNA and protein levels in large, well-phenotyped human cohorts may identify specific sub-populations most impacted by the functional consequences of this allele.

The strengths of this study are that the GWAS and RNA-seq findings are based on the analysis of a very large number of human samples, and the integrated analysis of short and longread RNA-seq data provides a high level of resolution to observe changes at the isoform level.

353 To our knowledge this is one of the first applications of long-read sequencing to human tissue 354 samples to demonstrate splicing-related effects of a GWAS-identified genetic variant. Important 355 limitations to consider are that long-read sequencing technologies can be affected by biases 356 related to transcript length, therefore direct comparisons of abundance between the short and 357 long isoforms of NPNT should be interpreted with caution. The most prominent finding in our 358 study, namely allele-specific alternative splice site usage, is clearly identified in isoforms of 359 equal length suggesting that these allele-specific observations are unlikely to be affected by this 360 bias. While there is strong statistical support for our findings, these are nonetheless correlative 361 findings from large human cohorts and future work is required to define the underlying 362 molecular mechanisms and provide further experimental evidence to demonstrate how these 363 mechanisms may alter COPD risk.

In summary, these analyses demonstrate that the pulmonary disease GWAS association near NPNT is very likely to be mediated by a common genetic variant that alters splicing, resulting in the insertion of a novel serine residue in the NPNT protein immediately downstream of the signal peptide domain. Given the known function of NPNT in extracellular matrix biology and the high expression of NPNT in lung tissue and pneumocytes³⁰, further investigation of the functional consequences of this splicing variant, including its effects on NPNT protein structure and function, are likely to elucidate causal mechanisms of COPD pathogenesis.

372 **Table 1.** Number of ONT reads containing 30bp sequences including and excluding the TAG

rs34712979	GAT <u>TAG</u> GTG	GATGTG
AA	825	206
AA	735	163
AA	291	92
AA	1638	403
AA	2041	500
GG	10	2216
GG	2	1519
GG	8	51
GG	6	502
GG	1	1553

373 sequence at the 5' end of the 2nd exon of NPNT.

374

376 Funding/Acknowledgements: This work was funded by R01 HL124233, R01 HL147326, R01

377 HL111527, U01 HL089897, U01 HL089856, R01HL125583, R01HL130512, T32HL007427.

- 378 Research reported in this publication was supported by the NHLBI and FDA Center for Tobacco
- 379 Products (CTP). The content is solely the responsibility of the authors and does not necessarily

380 represent the official views of the NIH or the Food and Drug Administration.

- 381 The Genotype-Tissue Expression (GTEx) Project was supported by the <u>Common Fund</u> of the
- 382 Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,
- 383 NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained
- 384 from: the GTEx Portal between January and August of 2020 and via the GTEx Terra Workspace
- 385 during the same time interval.
- 386

387 Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by

388 the National Heart, Lung and Blood Institute (NHLBI). Whole Genome Sequencing and

389 RNASeq for "NHLBI TOPMed: The Lung Tissue Research Consortium (phs001662)" was

- 390 performed at Northwest Genome Center (NWGC, HHSN268201600032I, RNASeq) and Broad
- 391 Genomics (HHSN268201600034I, WGS) Core support including centralized genomic read
- 392 mapping and genotype calling, along with variant quality metrics and filtering were provided by
- the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract
- 394 HHSN268201800002I). Core support including phenotype harmonization, data management,
- 395 sample-identity QC, and general program coordination were provided by the TOPMed Data
- Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We
- 397 gratefully acknowledge the studies and participants who provided biological samples and data
- 398 for TOPMed.
- 399

400 **COPDGene[®] Investigators – Core Units:**

401 *Administrative Center*: James D. Crapo, MD (PI); Edwin K. Silverman, MD, PhD (PI); Barry J.
 402 Make, MD; Elizabeth A. Regan, MD, PhD

- 403
- 404 Genetic Analysis Center: Terri Beaty, PhD; Ferdouse Begum, PhD; Peter J. Castaldi, MD, MSc;
- 405 Michael Cho, MD; Dawn L. DeMeo, MD, MPH; Adel R. Boueiz, MD; Marilyn G. Foreman,
- 406 MD, MS; Eitan Halper-Stromberg; Lystra P. Hayden, MD, MMSc; Craig P. Hersh, MD, MPH;
- 407 Jacqueline Hetmanski, MS, MPH; Brian D. Hobbs, MD; John E. Hokanson, MPH, PhD; Nan
- 408 Laird, PhD; Christoph Lange, PhD; Sharon M. Lutz, PhD; Merry-Lynn McDonald, PhD;

- 409 Margaret M. Parker, PhD; Dmitry Prokopenko, Ph.D; Dandi Qiao, PhD; Elizabeth A. Regan,
- 410 MD, PhD; Phuwanat Sakornsakolpat, MD; Edwin K. Silverman, MD, PhD; Emily S. Wan, MD;
- 411 Sungho Won, PhD
- 412
- 413 Imaging Center: Juan Pablo Centeno; Jean-Paul Charbonnier, PhD; Harvey O. Coxson, PhD;
- 414 Craig J. Galban, PhD; MeiLan K. Han, MD, MS; Eric A. Hoffman, Stephen Humphries, PhD;
- 415 Francine L. Jacobson, MD, MPH; Philip F. Judy, PhD; Ella A. Kazerooni, MD; Alex Kluiber;
- 416 David A. Lynch, MB; Pietro Nardelli, PhD; John D. Newell, Jr., MD; Aleena Notary; Andrea
- 417 Oh, MD; Elizabeth A. Regan, MD, PhD; James C. Ross, PhD; Raul San Jose Estepar, PhD;
- 418 Joyce Schroeder, MD; Jered Sieren; Berend C. Stoel, PhD; Juerg Tschirren, PhD; Edwin Van
- 419 Beek, MD, PhD; Bram van Ginneken, PhD; Eva van Rikxoort, PhD; Gonzalo Vegas Sanchez-Ferrero, PhD; Lucas Veitel; George R. Washko, MD; Carla G. Wilson, MS;
- 420 421
- 422 PFT QA Center, Salt Lake City, UT: Robert Jensen, PhD
- 423
- 424 Data Coordinating Center and Biostatistics, National Jewish Health, Denver, CO: Douglas
- 425 Everett, PhD; Jim Crooks, PhD; Katherine Pratte, PhD; Matt Strand, PhD; Carla G. Wilson, MS 426
- 427 Epidemiology Core, University of Colorado Anschutz Medical Campus, Aurora, CO: John E.
- 428 Hokanson, MPH, PhD; Gregory Kinney, MPH, PhD; Sharon M. Lutz, PhD; Kendra A. Young, 429 PhD
- 430
- 431 Mortality Adjudication Core: Surva P. Bhatt, MD; Jessica Bon, MD; Alejandro A. Diaz, MD,
- 432 MPH; MeiLan K. Han, MD, MS; Barry Make, MD; Susan Murray, ScD; Elizabeth Regan, MD;
- 433 Xavier Soler, MD; Carla G. Wilson, MS
- 434
- 435 Biomarker Core: Russell P. Bowler, MD, PhD; Katerina Kechris, PhD; Farnoush Banaei-
- 436 Kashani, Ph.D COPDGene[®] Investigators – Clinical Centers
- 437 Ann Arbor VA: Jeffrey L. Curtis, MD; Perry G. Pernicano, MD
- 438
- 439 Baylor College of Medicine, Houston, TX: Nicola Hanania, MD, MS; Mustafa Atik, MD; Aladin Boriek, PhD; Kalpatha Guntupalli, MD; Elizabeth Guy, MD; Amit Parulekar, MD;
- 440
- 441 442 Brigham and Women's Hospital, Boston, MA: Dawn L. DeMeo, MD, MPH; Alejandro A. Diaz,
- 443 MD, MPH; Lystra P. Hayden, MD; Brian D. Hobbs, MD; Craig Hersh, MD, MPH; Francine L.
- 444 Jacobson, MD, MPH; George Washko, MD
- 445
- 446 Columbia University, New York, NY: R. Graham Barr, MD, DrPH; John Austin, MD; Belinda D'Souza, MD; Byron Thomashow, MD
- 447 448
- 449 Duke University Medical Center, Durham, NC: Neil MacIntyre, Jr., MD; H. Page McAdams,
- 450 MD; Lacey Washington, MD
- 452 Grady Memorial Hospital, Atlanta, GA: Eric Flenaugh, MD; Silanth Terpenning, MD
- 453

454 455	HealthPartners Research Institute, Minneapolis, MN: Charlene McEvoy, MD, MPH; Joseph Tashjian, MD
456	
457	Johns Hopkins University, Baltimore, MD: Robert Wise, MD; Robert Brown, MD; Nadia N.
458	Hansel, MD, MPH; Karen Horton, MD; Allison Lambert, MD, MHS; Nirupama Putcha, MD,
459	MHS
460	
461	Lundquist Institute for Biomedical Innovationat Harbor UCLA Medical Center, Torrance, CA:
462	Richard Casaburi, PhD, MD; Alessandra Adami, PhD; Matthew Budoff, MD; Hans Fischer,
463	MD; Janos Porszasz, MD, PhD; Harry Rossiter, PhD; William Stringer, MD
464	1,22, Valios 1 0102002, 1,22, 1,12, 1101, 110001001, 1,12, ((1110011-00110B01, 1)22
465	Michael E. DeBakey VAMC, Houston, TX: Amir Sharafkhaneh, MD, PhD; Charlie Lan, DO
	Michael E. Debakey VAMC, Housion, IX. Anni Shararkhanch, MD, FhD, Charle Lan, DO
466	
467	Minneapolis VA: Christine Wendt, MD; Brian Bell, MD; Ken M. Kunisaki, MD, MS
468	
469	National Jewish Health, Denver, CO: Russell Bowler, MD, PhD; David A. Lynch, MB
470	
471	Reliant Medical Group, Worcester, MA: Richard Rosiello, MD; David Pace, MD
472	
473	Temple University, Philadelphia, PA: Gerard Criner, MD; David Ciccolella, MD; Francis
474	Cordova, MD; Chandra Dass, MD; Gilbert D'Alonzo, DO; Parag Desai, MD; Michael Jacobs,
475	PharmD; Steven Kelsen, MD, PhD; Victor Kim, MD; A. James Mamary, MD; Nathaniel
476	Marchetti, DO; Aditi Satti, MD; Kartik Shenoy, MD; Robert M. Steiner, MD; Alex Swift, MD;
477	Irene Swift, MD; Maria Elena Vega-Sanchez, MD
478	
479	University of Alabama, Birmingham, AL: Mark Dransfield, MD; William Bailey, MD; Surya P.
480	Bhatt, MD; Anand Iyer, MD; Hrudaya Nath, MD; J. Michael Wells, MD
481	
482	University of California San Diego, CA: Douglos Conrod MD: Vavier Soler, MD, DhD: Andrew
	University of California, San Diego, CA: Douglas Conrad, MD; Xavier Soler, MD, PhD; Andrew
483	Yen, MD
484	
485	University of Iowa, Iowa City, IA: Alejandro P. Comellas, MD; Karin F. Hoth, PhD; John
486	Newell, Jr., MD; Brad Thompson, MD
487	-
488	University of Michigan, Ann Arbor, MI: MeiLan K. Han, MD MS; Ella Kazerooni, MD MS;
489	Wassim Labaki, MD MS; Craig Galban, PhD; Dharshan Vummidi, MD
490	Wassini Labaki, WD Wis, Clarg Galban, ThD, Dharshan Vaninidi, WD
	U
491	University of Minnesota, Minneapolis, MN: Joanne Billings, MD; Abbie Begnaud, MD; Tadashi
492	Allen, MD
493	
494	University of Pittsburgh, Pittsburgh, PA: Frank Sciurba, MD; Jessica Bon, MD; Divay Chandra,
495	MD, MSc; Carl Fuhrman, MD; Joel Weissfeld, MD, MPH
496	
497	University of Texas Health, San Antonio, San Antonio, TX: Antonio Anzueto, MD; Sandra
498	Adams, MD; Diego Maselli-Caceres, MD; Mario E. Ruiz, MD; Harjinder Singh
499	Adams, MD, Diego Masem-Caceles, MD, Mario E. Ruiz, MD, Harjinder Singn
477	

- 500 **Conflict of Interest Statement**: P. Castaldi has received personal fees and grant support from
- 501 GlaxoSmithKline and Novartis. C.Hersh has received grants from NHLBI, Bayer, Boehringer-
- 502 Ingelheim, Novartis and Vertex. M. Cho has received grant support from GSK and Bayer, and
- 503 speaking or consulting fees from AstraZeneca and Illumina. E. Silverman has received grant
- 504 support from GSK and Bayer. A. Laederach reports grants from the NIH NHLBI and consultant
- 505 fees from Ribometrix. C. Vollmers has filed patent applications on aspects of the R2C2 method.
- 506

507 **References**

- 509 1. Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., Reeve, N.F., Guyatt, A.L., Jackson,
- 510 V.E., Shrine, N., Qiao, D., Bartz, T.M., Kim, D.K., et al. (2019). Genetic landscape of chronic
- 511 obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.
- 512 Nature Genetics *51*, 494–505.
- 513 2. Zhou, X., Baron, R.M., Hardin, M., Cho, M., Zielinski, J., Hawrylkiewicz, I., Sliwinski, P.,
- 514 Hersh, C.P., Mancini, J.D., Lu, K., et al. (2012). Identification of a chronic obstructive
- 515 pulmonary disease genetic determinant that regulates HHIP. Hum. Mol. Genet. 21, 1325–1335.
- 516 3. Castaldi, P.J., Guo, F., Qiao, D., Du, F., Naing, Z.Z.C., Li, Y., Pham, B., Mikkelsen, T.S.,
- 517 Cho, M., Silverman, E., et al. (2018). Identification of Functional Variants in the FAM13A
- 518 COPD GWAS Locus by Massively Parallel Reporter Assays. American Journal of Respiratory
- 519 and Critical Care Medicine *199*, 52–61.
- 520 4. Parker, M.M., Hao, Y., Guo, F., Pham, B., Chase, R., Platig, J., Cho, M., Hersh, C.P.,
- 521 Thannickal, V.J., Crapo, J.D., et al. (2019). Identification of an emphysema-associated genetic 522 variant near TGFB2 with regulatory effects in lung fibroblasts. Elife 8.
- 523 5. Boueiz, A., Pham, B., Chase, R., Lamb, A., Lee, S., Naing, Z.Z.C., Cho, M., Parker, M.M.,
- 524 Sakornsakolpat, P., Hersh, C.P., et al. (2019). Integrative Genomics Analysis Identifies
- ACVR1B as a Candidate Causal Gene of Emphysema Distribution. Am J Respir Cell Mol Biol 60, 388–398.
- 527 6. Li, Y.I., van de Geijn, B., Raj, A., Knowles, D.A., Petti, A.A., Golan, D., Gilad, Y., and
- 528 Pritchard, J.K. (2016). RNA splicing is a primary link between genetic variation and disease.
 529 Science 352, 600–604.
- 530 7. Saferali, A., Yun, J.H., Parker, M.M., Sakornsakolpat, P., Chase, R.P., Lamb, A., Hobbs, B.D.,
- 531 Boezen, M.H., Dai, X., de Jong, K., et al. (2019). Analysis of genetically driven alternative
- 532 splicing identifies FBXO38 as a novel COPD susceptibility gene. PLoS Genet 15, e1008229.
- 533 8. Shrine, N., Guyatt, A.L., Erzurumluoglu, A.M., Jackson, V.E., Hobbs, B.D., Melbourne, C.A.,
- 534 Batini, C., Fawcett, K.A., Song, K., Sakornsakolpat, P., et al. (2019). New genetic signals for
- 535 lung function highlight pathways and chronic obstructive pulmonary disease associations across
- 536 multiple ancestries. Nature Genetics *51*, 481–493.
- 537 9. The GTEx Consortium (2020). The GTEx Consortium atlas of genetic regulatory effects
 538 across human tissues. Science *369*, 1318–1330.
- 539 10. Farh, K.K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., Shoresh, N.,
- 540 Whitton, H., Ryan, R.J.H., Shishkin, A.A., et al. (2015). Genetic and epigenetic fine mapping of 541 causal autoimmune disease variants. Nature *518*, 337–343.
- 542 11. Wu, E., Nance, T., and Montgomery, S.B. (2014). SplicePlot: a utility for visualizing splicing 543 quantitative trait loci. Bioinformatics *30*, 1025–1026.

- 544 12. Picelli, S., Faridani, O.R., Björklund, Å.K., Winberg, G., Sagasser, S., and Sandberg, R.
- 545 (2014). Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 9, 171–181.
- 546 13. Byrne, A., Supple, M.A., Volden, R., Laidre, K.L., Shapiro, B., and Vollmers, C. (2019).
- 547 Depletion of Hemoglobin Transcripts and Long-Read Sequencing Improves the Transcriptome
- 548 Annotation of the Polar Bear (Ursus maritimus). Front Genet 10, 403.
- 549 14. Volden, R., Palmer, T., Byrne, A., Cole, C., Schmitz, R.J., Green, R.E., and Vollmers, C.
- 550 (2018). Improving nanopore read accuracy with the R2C2 method enables the sequencing of
- 551 highly multiplexed full-length single-cell cDNA. Proceedings of the National Academy of
- 552 Sciences 115, 9726–9731.
- 553 15. Cole, C., Byrne, A., Adams, M., Volden, R., and Vollmers, C. (2020). Complete
- 554 characterization of the human immune cell transcriptome using accurate full-length cDNA 555 sequencing. Genome Res. *30*, 589–601.
- 556 16. Volden, R., and Vollmers, C. (2020). Highly Multiplexed Single-Cell Full-Length cDNA
- 557 Sequencing of human immune cells with 10X Genomics and R2C2. bioRxiv 20, 2020.01.10.902361.
- 558 2020.01.10.902501.
 - 559 17. Tardaguila, M., la Fuente, de, L., Marti, C., Pereira, C., Pardo-Palacios, F.J., Del Risco, H.,
 - 560 Ferrell, M., Mellado, M., Macchietto, M., Verheggen, K., et al. (2018). SQANTI: extensive
 - 561 characterization of long-read transcript sequences for quality control in full-length transcriptome
 - identification and quantification. Genome Res. 28, 396–411.
 - 18. UniProt Consortium (2019). UniProt: a worldwide hub of protein knowledge. Nucleic Acids
 Research 47, D506–D515.
 - 18. Kumar, T., (2013). CFSSP: Chou and Fasman secondary structure prediction server. Wide
 Spectrum *1*(9), 15–19.
- 567 20. Hiller, M., Huse, K., Szafranski, K., Jahn, N., Hampe, J., Schreiber, S., Backofen, R., and
- 568 Platzer, M. (2004). Widespread occurrence of alternative splicing at NAGNAG acceptors 569 contributes to proteome plasticity. Nature Genetics *36*, 1255–1257.
- 570 21. Bradley, R.K., Merkin, J., Lambert, N.J., and Burge, C.B. (2012). Alternative splicing of 571 RNA triplets is often regulated and accelerates proteome evolution. PLoS Biol. *10*, e1001229.
- 572 22. Brandenberger, R., Schmidt, A., Linton, J., Wang, D., Backus, C., Denda, S., Müller, U., and 573 Reichardt, L.F. (2001). Identification and characterization of a novel extracellular matrix protein
- 574 nephronectin that is associated with integrin alpha8beta1 in the embryonic kidney. J. Cell Biol.
- 575 154, 447–458.
- 576 23. Morimura, N., Tezuka, Y., Watanabe, N., Yasuda, M., Miyatani, S., Hozumi, N., and
- 577 Tezuka, K.-I. (2001). Molecular Cloning of POEM: A Novel Adhesion Molecule That Interacts
- 578 With $\alpha 8\beta 1$ Integrin. Journal of Biological Chemistry 276, 42172–42181.

- 579 24. Linton, J.M., Martin, G.R., and Reichardt, L.F. (2007). The ECM protein nephronectin
- promotes kidney development via integrin alpha8beta1-mediated stimulation of Gdnf expression. 580 581
- Development 134, 2501-2509.

582 25. Kahai, S., Lee, S.-C., Seth, A., and Yang, B.B. (2010). Nephronectin promotes osteoblast 583 differentiation via the epidermal growth factor-like repeats. FEBS Lett. 584, 233–238.

- 584 26. Steigedal, T.S., Toraskar, J., Redvers, R.P., Valla, M., Magnussen, S.N., Bofin, A.M.,
- 585 Opdahl, S., Lundgren, S., Eckhardt, B.L., Lamar, J.M., et al. (2018). Nephronectin is Correlated
- 586 with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs.
- 587 Neoplasia 20, 387–400.
- 588 27. Lee, S., Honda, M., Yamamoto, S., Kumagai-Takei, N., Yoshitome, K., Nishimura, Y., Sada,
- 589 N., Kon, S., and Otsuki, T. (2019). Role of Nephronectin in Pathophysiology of Silicosis. Int J 590 Mol Sci 20, 2581.
- 591 28. Toraskar, J., Magnussen, S.N., Hagen, L., Sharma, A., Hoang, L., Bjørkøy, G., Svineng, G.,
- 592 and Steigedal, T.S. (2019). A Novel Truncated Form of Nephronectin Is Present in Small
- 593 Extracellular Vesicles Isolated from 66cl4 Cells. J. Proteome Res. 18, 1237–1247.
- 594 29. Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
- 595 Sivertsson, A., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map 596 of the human proteome. Science 347, 1260419-1260419.
- 597 30. Obeidat, M., Hao, K., Bossé, Y., Nickle, D.C., Nie, Y., Postma, D.S., Laviolette, M.,
- 598 Sandford, A.J., Daley, D.D., Hogg, J.C., et al. (2015). Molecular mechanisms underlying
- 599 variations in lung function: a systems genetics analysis. Lancet Respir Med 3, 782–795.
- 600 31. Hancock, D., Eijgelsheim, M., Wilk, J.B., Gharib, S., Loehr, L., Marciante, K., Franceschini,
- 601 N., Durme, Y., Chen, T.-H., Barr, R.G., et al. (2010). Meta-analyses of genome-wide association 602 studies identify multiple loci associated with pulmonary function. Nature Genetics 42, 45–52.
- 603 32. Parker, M.M., Foreman, M.G., Abel, H.J., Mathias, R.A., Hetmanski, J.B., Crapo, J.D., 604 Silverman, E., Beaty, T.H., COPDGene Investigators (2014). Admixture mapping identifies a
- 605 quantitative trait locus associated with FEV1/FVC in the COPDGene Study. Genet. Epidemiol. 606 38,652–659.
- 607 33. Soler Artigas, M., Wain, L.V., Miller, S., Kheirallah, A.K., Huffman, J.E., Ntalla, I., Shrine,
- 608 N., Obeidat, M., Trochet, H., McArdle, W.L., et al. (2015). Sixteen new lung function signals 609 identified through 1000 Genomes Project reference panel imputation. Nat Commun 6, 8658.
- 610 34. Obeidat, M., Miller, S., Probert, K., Billington, C.K., Henry, A.P., Hodge, E., Nelson, C.P.,
- 611 Stewart, C.E., Swan, C., Wain, L.V., et al. (2013). GSTCD and INTS12 regulation and
- 612 expression in the human lung. PLoS ONE 8, e74630.
- 613 35. Wain, L.V., Shrine, N., Artigas, M.S., Erzurumluoglu, A.M., Noyvert, B., Bossini-Castillo,
- 614 L., Obeidat, M., Henry, A.P., Portelli, M.A., Hall, R.J., et al. (2017). Genome-wide association

- 615 analyses for lung function and chronic obstructive pulmonary disease identify new loci and
- 616 potential druggable targets. Nature Genetics 49, 416–425.